Find Trials
BLADDER
BREAST - High Risk after Surgery
High Risk Breast Cancer after Surgery
Protocol Title: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine‐Based Therapy Without Disease Recurrence
GASTROINTESTINAL
HEAD AND NECK
LUNG CANCER
Lung cancer
Protocol Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicentre,
International Study of Durvalumab and Domvanalimab (AB154) as Sequential Therapy in
Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer
Whose Disease has not Progressed Following Definitive, Platinum-based Concurrent
Chemoradiation Therapy (PACIFIC 8)
Protocol Number: D9075C00001
LUNG CANCER - Metastatic Non-Small Cell Lung Cancer
Metastatic Non-Small Cell Lung Cancer
Protocol Title: A Phase III, Two- Arm, Parallel, Randomized, Multi-Center,Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Versus Pembrolizumab in Combination with Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) (eVOLVE-Lung02)
Protocol Number: (D798AC00001).
LUNG CANCER - Unresectable Pleural Mesothelioma
Unresectable Pleural Mesothelioma
Protocol Title: A Phase III, Randomized, Open-Label, Multicenter, Global Study of
Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural Mesothelioma (eVOLVE-Meso)
Protocol Number: D7988C00001